| Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: the Fremantle Diabetes Study. | |
| | |
MedLine Citation:
|
PMID: 20839379 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: There is cross-sectional evidence that CagA antigen produced by Helicobacter pylori is associated with coronary heart disease, stroke, atrial fibrillation (AF) and microalbuminuria, but no large-scale longitudinal studies have been conducted in diabetic patients. We aimed to determine whether cytotoxin-associated gene-A (CagA) seropositivity is independently associated with important vascular outcomes in type 2 diabetes. METHODS: We studied 1179 type 2 patients from a well characterized community-based cohort who had available sera from baseline assessment between 1993 and 1996, and follow-up for incident events to end-June 2007. H. pylori IgG and CagA antibodies at baseline were measured by validated ELISA. Multiple logistic/linear regression analysis and Cox proportional hazards modelling were used to determine independent baseline associates of prevalent and incident complications, respectively, including H. pylori/CagA serostatus. RESULTS: At baseline, 62.0% of patients were H. pylori seropositive and 37.7% were both H. pylori and CagA seropositive. CagA seropositivity was not independently associated with prevalent coronary heart disease (CHD), cerebrovascular disease (CVD), peripheral arterial disease or AF at baseline (P > 0.41), but there was a significant inverse association with ln(urinary albumin:creatinine) (P = 0.033). There were no independent associations between CagA seropositivity and incident CHD/CVD or progression to microalbuminuria (P > 0.20). During follow-up, 480 patients (40.7%) died, 246 (50.2%) from cardiovascular causes. After adjustment for other variables,CagA seropositivity was weakly protective against cardiovascular death (P = 0.024). CONCLUSION: CagA seropositivity is not a risk factor for chronic vascular complications of type 2 diabetes. Assay of CagA antibodies does not contribute significantly to clinical management outside gastroenterological indications. |
| | |
Authors:
|
Katrin Schimke; Stephen A P Chubb; Wendy A Davis; Timothy M E Davis |
Related Documents
:
|
18804209 - Increased levels of endothelial microparticles cd144 (ve-cadherin) positives in type 2 ... 19620249 - Diabetes and cancer. 19427049 - Cigarette smoking, smoking cessation, and diabetes. 19643439 - Metabolic abnormalities and cardiovascular risk factors in children with myositis. 17767009 - Is family history a useful tool for detecting children at risk for diabetes and cardiov... 7028539 - Diabetes and atherosclerosis: an overview. 22078109 - The prevalence and risk factors of an abnormal ankle-brachial index in patients with ty... 19752219 - Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybr... 11321889 - Muscle fiber composition and capillarization in relation to metabolic alterations in hy... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Atherosclerosis Volume: 212 ISSN: 1879-1484 ISO Abbreviation: Atherosclerosis Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-13 Completed Date: 2010-12-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland |
Other Details:
|
Languages: eng Pagination: 321-6 Citation Subset: IM |
Affiliation:
|
School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antibodies, Bacterial / blood* Antigens, Bacterial / immunology* Australia Bacterial Proteins / immunology* Cardiovascular Diseases / etiology*, microbiology, mortality Cause of Death Diabetes Complications / etiology*, microbiology, mortality Diabetes Mellitus, Type 2 / complications*, mortality Enzyme-Linked Immunosorbent Assay Female Helicobacter Infections / complications, microbiology*, mortality Helicobacter pylori / immunology* Humans Incidence Kaplan-Meier Estimate Linear Models Logistic Models Longitudinal Studies Male Middle Aged Prevalence Proportional Hazards Models Risk Assessment Risk Factors Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Bacterial; 0/Antigens, Bacterial; 0/Bacterial Proteins; 0/cagA protein, Helicobacter pylori |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Upconverted photoluminescence in Ho(3+) and Yb(3+) codoped Gd(2) O(3) nanocrystals with and without ...
Next Document: Does speciation matter for tungsten ecotoxicology?